Skip to content
Screener

Stock-Based Comp at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$243M-3.5%
Opus Genetics logo
Opus GeneticsIRD
$1.46M+60.4%
Regenxbio logo
RegenxbioRGNX
$9.05M+4.6%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$9.18M-36.7%
Prime Medicine logo
Prime MedicinePRME
$4.87M-23.1%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$4.45M-36.3%

Other financials

Income statement

See full
Revenue$293.0K-84.8%
Operating income-$40.8M+1.9%
Net income-$46.3M-15.8%
EPS (diluted)-$0.57-11.8%

Balance sheet

See full
Cash & equivalents$71.5M+7.5%
Total debt$62.7M-22.5%
Total equity-$58.1M-276%
Total assets$244.7M+9.2%

Cash flow

See full
Operating cash flow$17.8M+148%
CapEx$2.0M+17.4%
Free cash flow$15.8M+141%

Valuation

See full
Market cap$1.18B+85.4%
Enterprise value$1.18B+71.1%
P/S14.9×-2.0×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%
Debt / equity27.2×+26.1×
Current ratio0.5×-1.0×

Where this comes from

Reported directly by MeiraGTx Holdings plc in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: MeiraGTx Holdings plc’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060739
Line itemFor the Three-Month Periods Ended March 31, 2026For the Three-Month Periods Ended March 31, 2025
Cash flows from operating activities:
Net loss$(46,313)$(39,981)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense3,6544,887
Foreign currency loss (gain)2,837(3,687)
Depreciation and amortization3,0083,081
Change in right-of-use assets6534,299
Gain on termination of lease liabilities(1,365)

Item 1. Financial Statements (Unaudited)

FAQ

What is MeiraGTx Holdings plc's stock-based comp?
MeiraGTx Holdings plc (MGTX) reported stock-based comp of $3.65M in Q1 2026.
How has MeiraGTx Holdings plc's stock-based comp changed year-over-year?
MeiraGTx Holdings plc's stock-based comp decreased by 25.2% year-over-year, from $4.89M to $3.65M.
What is the long-term trend for MeiraGTx Holdings plc's stock-based comp?
Over 4 years (2021 to 2025), MeiraGTx Holdings plc's stock-based comp has grown at a 1.5% compound annual growth rate (CAGR), from $20.78M to $22.1M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about MeiraGTx Holdings plc's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude